Story perspectives

Revolutionary Advances in Gene Therapies Transform Healthcare Landscape

10/21/2025

Summary

Story summary

Becton, Dickinson and Company and Gilead Sciences are enhancing drug delivery for cell and gene therapies, improving accessibility.
Blood-based biomarker tests for Alzheimer’s disease are gaining traction, offering cost-effective alternatives to traditional diagnostics.
Editas Medicine reported promising preclinical results for its LDL-cholesterol therapy, EDIT-401.
Intellia Therapeutics reported Phase I/II results for its gene editing candidate, lonvoguran ziclumeran, in hereditary angioedema.
These developments signal a shift toward innovative, less invasive treatments.

1 of 1

Story summary

Becton, Dickinson and Company and Gilead Sciences are enhancing drug delivery for cell and gene therapies, improving accessibility.
Blood-based biomarker tests for Alzheimer’s disease are gaining traction, offering cost-effective alternatives to traditional diagnostics.
Editas Medicine reported promising preclinical results for its LDL-cholesterol therapy, EDIT-401.
Intellia Therapeutics reported Phase I/II results for its gene editing candidate, lonvoguran ziclumeran, in hereditary angioedema.
These developments signal a shift toward innovative, less invasive treatments.